Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the 13 Most Undervalued Stocks Under $20 to Buy. On October 31, Piper Sandler lifted its price target on the stock to $13 from $11, while maintaining an Overweight rating on its shares.

The adjustment followed the company’s third quarter 2025 earnings call on October 30. Piper Sandler noted the strong quarterly results that beat Wall Street’s estimates for both revenue and earnings.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) reported a net revenue of $785 million, up 12% from the prior year’s period and beating forecasts of $774 million. The results reflected the strength of the company’s diversified business portfolio.

Speciality net revenue was up 8%, while revenue for Affordable Medicines also grew 8% during the quarter. AvKARE was another major contributor, with the segment top line surging 24% year-over-year.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s net income stood at $54.4 million, improving substantially from a net loss of $50.6 million last year. Diluted EPS was posted at $0.17, beating estimates by four cents and up 6% year-over-year.

Adjusted EBITDA for the quarter was $160 million, up 1% year-over-year, driven by higher revenue. However, the figure was partially offset by investments on new launches and a raise in R&D expenditure.

The company also updated its guidance for the full year 2025. While net revenue is expected to remain in the same range of $3 billion to $3.1 billion, adjusted EPS is now anticipated between $0.75 and $0.80, up from the previous guidance of $0.70 to $0.75.

Moreover, the lower end of adjusted EBITDA has been raised by $10 million, with the new range now between $675 million and $685 million.

The stock has had robust returns in 2025, surging over 50% year-to-date.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a biopharmaceutical company with expertise in developing, marketing, and distributing a wide range of medicines.

While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: ChatGPT Stock Advice: Top 8 Defense Stocks and 10 Largest Defense Stocks in 2025.

Disclosure: None.